ADT + enzalutamide in mHSPC … outcome of the ARCHES trial

Pfizer and Astellas have, this morning, announced that the addition of enzalutamide to standard androgen deprivation (ADT) has led to improved outcomes in men with metastatic, hormone-sensitive prostate cancer (mHSPC). … READ MORE …

The potential for use of enzalutamide in HSPC: an update

We note that Pfizer and Astellas have recently modified the protocols for two large, international, randomized, Phase III clinical trials to see if they can get earlier results that might affect the potential for use of enzalutamide (Xtandi) in some groups of men with hormone-sensitive prostate cancer (HSPC). … READ MORE …

Astellas, Medivation initiate new Phase III ARCHES trial

According to a media release issued today by Astellas Pharma and Medivation, the companies have just initiated a new, Phase III, pivotal trial of enzalutamide in men with advanced prostate cancer. … READ MORE …